Join the Xtampza ER group to help and get support from people like you.
Xtampza ER News
Opioids Tough To Prescribe For Legitimate Patients, Doctors Say
THURSDAY, April 24, 2025 — Patients who legitimately need opioid painkillers are finding it more difficult to get the meds they need, due to guardrails established in response to the U.S. opioid c...
OD Deaths Decline in U.S., Driven By Drop In Opioid Fatalities
FRIDAY, Feb. 21, 2025 – America’s opioid crisis is showing signs of subsiding, a new report from the U.S. Centers for Disease Control and Prevention (CDC) says. Drug overdose deaths (OD) decreased b...
Painkiller Misuse Common Among People Battling Chronic Pain
THURSDAY, Aug. 8, 2024 – Nearly 1 in every 10 chronic pain patients treated with prescription opioids winds up addicted to the painkillers at some point, a new review finds. Further, nearly 1 in 3...
Supreme Court Rejects Purdue Pharma Opioid Settlement
FRIDAY, June 28, 2024 – The U.S. Supreme Court on Thursday struck down a controversial settlement that drug maker Purdue Pharma had reached with victims of the opioid epidemic. The ruling threatens...
Supreme Court Rejects Purdue Pharma Opioid Settlement
FRIDAY, June 28, 2024 – The U.S. Supreme Court on Thursday struck down a controversial settlement that drug maker Purdue Pharma had reached with victims of the opioid epidemic. The ruling threatens...
FDA Medwatch Alert: Drug Safety Communication: All Opioid Pain Medicines - FDA Updates Prescribing Information to Provide Additional Guidance for Safe Use
ISSUE: The FDA is requiring several updates to the prescribing information for both immediate-release (IR) and extended release/long acting (ER/LA) opioid pain medicines. This includes stating for a...
FDA Medwatch Alert: Opioid Pain or Cough Medicines Combined With Benzodiazepines: Drug Safety Communication - FDA Requiring New Boxed Warnings About Serious Risks and Death
ISSUE: FDA review has found that the growing combined use of opioid medicines with benzodiazepines or other drugs that depress the central nervous system (CNS) has resulted in serious side effects,...
Collegium Receives FDA Approval for Xtampza ER, an Analgesic with Abuse-Deterrent Properties
CANTON, Mass., April 26, 2016 (GLOBE NEWSWIRE) – Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that the U.S. Food and Drug Administration (FDA) approved Xtampza ER (oxycodone)...